文献速递系统性红斑狼疮

系统性红斑狼疮国际协作组(SLICC)起始队列中抗核抗体的纵向分析

Longitudinal analysis of ANA in the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort.
PubMed 文献 · Ann Rheum Dis · 2022-03-25

该研究在805例新发系统性红斑狼疮(SLE)患者中,于入组时、第3年和第5年比较了两种HEp-2间接免疫荧光法(IFA1、IFA2)和一种ELISA法检测抗核抗体(ANA)的结果。三种方法阳性率均高且一致性较好,但5年随访中ELISA阳性率有所下降。作者认为,当考虑SLE诊断时,ELISA或HEp-2 IFA任一阴性可能需要反射检测。

要点

  • 入组时至少一种ANA检测阳性者占99.6%,IFA1、IFA2和ELISA阳性率分别为96.1%、98.3%和96.6%。
  • 第5年IFA1和IFA2阳性率仍高(95.2%、98.9%),ELISA阳性率降至91.3%(p<0.001)。
  • 两种IFA在各时间点ANA阳性一致率>91%,荧光模式一致率≥71%。

核心结论

  • 在新发SLE中,三种ANA检测方法表现出可互换性,阳性比例及滴度或吸光度单位均高。
  • 5年随访期间ANA检测性能仅有轻度变异。
  • 在考虑SLE诊断的临床情形下,ELISA或HEp-2 IFA任一检测阴性可能需要反射检测。

研究设计与样本

  • 纵向分析国际新发SLE起始队列,患者定期复检并随访5年。
  • 纳入805例SLE患者,采集入组时、第3年和第5年的人口学、临床和血清学数据。
  • 在同一实验室进行两种HEp-2间接免疫荧光法(IFA1、IFA2)、一种ANA ELISA以及SLE相关自身抗体检测。
  • 采用McNemar、Wilcoxon和kappa统计分别比较阳性频率、滴度或吸光度单位(AU)以及IFA荧光模式。

主要发现

  • 入组时ANA阳性(≥1:80)率:IFA1为96.1%(中位滴度1:1280,IQR 1:640-1:5120),IFA2为98.3%(1:2560,IQR 1:640-1:5120),ELISA为96.6%(176.3 AU,IQR 106.4 AU-203.5 AU)。
  • 入组时至少一种ANA检测阳性的患者占99.6%。
  • 第5年IFA1阳性率为95.2%,IFA2为98.9%,ELISA阳性率降至91.3%(p<0.001)。
  • IFA1与IFA2之间ANA阳性一致率在所有时间点均>91%,荧光模式一致率≥71%。

关键数值与推荐

  • 入组时ANA阳性(≥1:80)率:IFA1 96.1%,IFA2 98.3%,ELISA 96.6%。
  • 入组时中位滴度或吸光度单位:IFA1 1:1280(IQR 1:640-1:5120),IFA2 1:2560(IQR 1:640-1:5120),ELISA 176.3 AU(IQR 106.4 AU-203.5 AU)。
  • 第5年ANA阳性率:IFA1 95.2%,IFA2 98.9%,ELISA 91.3%(p<0.001)。
  • IFA1与IFA2之间ANA阳性一致率>91%,荧光模式一致率≥71%。

临床怎么用

  • 原文结论指出,在考虑SLE诊断的临床情形下,ELISA或HEp-2 IFA任一检测阴性可能需要反射检测。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: A perception derived from cross-sectional studies of small systemic lupus erythematosus (SLE) cohorts is that there is a marked discrepancy between antinuclear antibody (ANA) assays, which impacts on clinicians' approach to diagnosis and follow-up. We compared three ANA assays in a longitudinal analysis of a large international incident SLE cohort retested regularly and followed for 5 years. METHODS: Demographic, clinical and serological data was from 805 SLE patients at enrolment, year 3 and 5. Two HEp-2 indirect immunofluorescence assays (IFA1, IFA2), an ANA ELISA, and SLE-related autoantibodies were performed in one laboratory. Frequencies of positivity, titres or absorbance units (AU), and IFA patterns were compared using McNemar, Wilcoxon and kappa statistics, respectively. RESULTS: At enrolment, ANA positivity (≥1:80) was 96.1% by IFA1 (median titre 1:1280 (IQR 1:640-1:5120)), 98.3% by IFA2 (1:2560 (IQR 1:640-1:5120)) and 96.6% by ELISA (176.3 AU (IQR 106.4 AU-203.5 AU)). At least one ANA assay was positive for 99.6% of patients at enrolment. At year 5, ANA positivity by IFAs (IFA1 95.2%; IFA2 98.9%) remained high, while there was a decrease in ELISA positivity (91.3%, p<0.001). Overall, there was >91% agreement in ANA positivity at all time points and ≥71% agreement in IFA patterns between IFA1 and IFA2. CONCLUSION: In recent-onset SLE, three ANA assays demonstrated commutability with a high proportion of positivity and titres or AU. However, over 5 years follow-up, there was modest variation in ANA assay performance. In clinical situations where the SLE diagnosis is being considered, a negative test by either the ELISA or HEp-2 IFA may require reflex testing.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Choi MY, Clarke AE, Urowitz M, et al. Longitudinal analysis of ANA in the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. Ann Rheum Dis. 2022. PMID: 35338033. doi:10.1136/annrheumdis-2022-222168

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。